Phase 2 Tuberculosis Trial, Recruiting NCT07073638 Sponsor: Thirty Respiratory Limited Condition: Tuberculosis
Back to Tuberculosis

Phase 2 Tuberculosis Trial, Recruiting

NCT07073638
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign a consent form and take part in all parts of the trial
  • People who weigh between 40 and 90 kg (measured in light clothing, without shoes)
  • People who have been recently diagnosed with pulmonary tuberculosis (TB affecting the lungs)
  • People whose TB has been tested and found to be treatable with the antibiotic rifampicin (i.e., the TB is not resistant to it)
  • People who are able to produce a sufficient amount of sputum (mucus coughed up from the lungs), based on an overnight collection sample of roughly 10 mL or more
  • People whose lung function test (a breathing test called spirometry) shows a result of at least 40% during the screening stage
  • People who are not able to become pregnant, or who are willing to use effective contraception methods as defined by the trial (confirm with trial site for specific requirements)

Who may not be able to join:

  • People who are HIV positive and also have a low immune cell count (CD4 below 350 cells/mm³), or who are currently taking HIV antiviral medication
  • People whose blood shows a baseline methemoglobin level above 3% (a measure of a certain form of haemoglobin in the blood — confirm with trial site)
  • People who are currently pregnant or breastfeeding
  • People who are planning to become pregnant during the trial period or within at least 90 days after taking the last dose of the trial medicine
  • People who have taken part in another clinical trial involving an experimental medicine within the 8 weeks before screening
  • People who have already received any treatment for the current episode of TB that acts against the TB bacteria
  • People who have taken immune-suppressing medications — such as TNF-alpha inhibitors — within 2 weeks before screening, or who have taken steroid tablets or similar medications for more than 7 days within the 2 weeks before screening
  • People who have taken nitric oxide (NO) or related medicines, certain medicines that affect blood vessel function (phosphodiesterase inhibitors), or lung surfactant drugs within 30 days before screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Thirty Respiratory Limited
Registry
ClinicalTrials.gov
Start date
13 October 2025
Est. completion
15 September 2026

Where this trial is recruiting

🇿🇦 South Africa

Primary endpoints

Safety and Tolerability of Inhaled RESP30TB Measured as Number of Treatment Emergent Adverse Events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov